Abiraterone trials for Prostate cancer

All Abiraterone trials · All Prostate cancer trials

Phase breakdown

Recruiting trials studying Abiraterone for Prostate cancer

• A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
  NCT06863272 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 82 locations
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
  NCT05914116 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 107 locations
• A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
  NCT07226986 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 22 locations
• A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
  NCT06764485 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 281 locations
• A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
  NCT07570979 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 3 locations
• A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT07287150 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 48 locations
• AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
  NCT07611110 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 132 locations
• Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
  NCT07237269 · Phase: Phase 2 · Ages: 30 Years and older · Sex: Male · 1 location
• Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
  NCT06173362 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
  NCT06592924 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 395 locations
• Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)
  NCT05404139 · Phase: Phase 2 · Ages: 18 Years to 100 Years · Sex: Male · 2 locations
• Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
  NCT04175431 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 2 locations
• Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
  NCT03678025 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 338 locations
• Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
  NCT06378866 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 3 locations
• Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
  NCT07140900 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 16 locations
• Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT04221542 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 57 locations
• The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
  NCT06520345 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 33 locations
• TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
  NCT07190300 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 31 locations

Common questions

How many trials study Abiraterone for Prostate cancer?

18 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.